不同剂量前列地尔联合依帕司他治疗糖尿病痛性神经病变疗效观察  

Different doses of alprostadil combined with epalrestat treatment efficacy observation of diabetic painful nerve lesions

作　　者：金海加 任芳 

机构地区：[1]武警浙江总队嘉兴医院,嘉兴314000

出　　处：《中国新药杂志》2014年第12期1427-1430,1437,共5页Chinese Journal of New Drugs

摘　　要：目的:观察不同剂量前列地尔联合依帕司他治疗糖尿病痛性神经病变的临床效果及用药安全性。方法:将90例入选患者随机按1∶1分为对照组、观察A组及观察B组各30例,3组患者在性别、年龄、糖尿病病程、血压、血脂(低密度脂蛋白)、周围神经病变程度及血糖控制方面无差异,3组在血糖血压及血脂控制均达标的基础上均予以口服甲钴胺片、依帕司他(50 mg tid)等营养周围神经药基础治疗;观察A组基础治疗加用前列地尔10μg+0.9%氯化钠100 mL静脉滴注,qd;观察B组基础治疗加用前列地尔20μg+0.9%氯化钠100 mL静脉滴注,qd。连续用药3周后比较各组治疗前后疼痛缓解程度、临床疗效及正中神经、腓总神经MCV及SCV变化情况并观察临床用药安全性指标。结果:对照组、观察A及B组总有效率分别为53.3%,80.0%及90.0%;3组治疗后VAS评分间差异均有统计学意义(P<0.05);对照组治疗前后正中神经MCV及SCV值比较其差异有统计学意义(P<0.05),观察A,B两组正中神经、腓总神经MCV及SCV值治疗前后值,分别比较其差异均有统计学意义(P<0.05);观察A,B两组间治疗后正中神经、腓总神经MCV及SCV值,比较其差异有统计学意义(P<0.05)。各组患者治疗前后临床用药安全性指标监测无明显变化。结论:不同剂量的前列地尔联合依帕司他治疗可提高糖尿病痛性神经病变临床疗效,尤以较高剂量组疗效更佳,无明显不良反应。Objective：To observe the clinical effect and safety of different dosage of alprostadil combined with epalrestat in treatment of diabetic painful neuropathy. Methods： 90 patients were randomly divided into control group, group A and group B, 30 cases in each group. There was no significant difference in gender, age, duration of diabetes, blood pressure, blood lipid （LDL） , the degree of neuropathy and peripheral blood glucose of the three groups control. All groups were maintained or optimization of blood glucose, blood pressure and lipid risk factors control the program and to mecobalamin tablets（0.5 rag, rid） and epalrestat （50 rag, tid）. Group A were treated with 10 μg alprostadil （0.9% 100 mL sodium chloride infusion, qd）. Group B were treated with 20 p,g alprostadil （0.90/o sodium chloride 100 mL intravenous infusion, qd）. After continuous administration of 3 weeks, we observed and compared the clinical curative effect and the degree of pain relief, the median nerve, common peroneal nerve and the changes of MCV SCV and observe the clinical medication safety index before and after treatment. Results： The total effective rate of control group, group A and B were 53.3% , 80% and 90% , respective ly. There was statistically significant difference in VAS score among the three groups after treatment （P 〈 0.05） ; the control group before and after treatment of MCV of median nerve and SCV value comparison difference has sta- tistics significance （P 〈 0.05）. Median nerve, common peroneal nerve MCV and SCV of Group A and B before and after treatment were compared to the values with statistically significant （P 〈 0.05）. The valuethe difference of median nerve, common peroneal nerve MCV and SCV between Group A and B after treatment had statistical signifi- cance （ P 〈 0.05 ）. Safety monitoring indexof clinical medication had no obviously change after treatment in each group. Conclusion： Different doses of alprostadil combined with epalrestat treatment canimprove the cl

关 键 词：糖尿病 神经病变 依帕司他 前列地尔 

分 类 号：R972[医药卫生—药品]